Myriad Genetics Inc (MYGN)

Days of sales outstanding (DSO)

Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Receivables turnover 6.50 6.75 6.49 6.52 6.35 6.23 5.81 6.65 8.03 7.57 8.26 9.27 7.12 6.22 5.85 6.73 8.84 7.14 6.58 6.75
DSO days 56.14 54.09 56.25 55.97 57.48 58.56 62.83 54.92 45.46 48.22 44.20 39.38 51.28 58.64 62.41 54.20 41.27 51.10 55.45 54.05

September 30, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 6.50
= 56.14

Days of Sales Outstanding (DSO) is a financial ratio that measures the average number of days a company takes to collect revenue after making a sale. A lower DSO indicates faster collections and better cash flow management.

Analyzing the DSO trend for Myriad Genetics Inc over the past several quarters, we observe fluctuations in the metric. In the most recent quarter ending on September 30, 2024, the DSO stood at 56.14 days, which is slightly higher compared to the previous quarter's DSO of 54.09 days. This increase suggests a potential delay in collecting receivables, which may impact the company's cash conversion cycle.

Looking further back, the trend shows variability in DSO figures over the past few quarters. The DSO has ranged from a low of 39.38 days in March 2022 to a high of 62.83 days in March 2023. The highest DSO indicates a longer collection period, which could be a concern for working capital management.

It is important for Myriad Genetics Inc to closely monitor and manage its DSO to ensure efficient collection practices and maintain healthy cash flow. By focusing on improving invoice processes, managing credit terms, and actively following up on outstanding payments, the company can potentially reduce its DSO and enhance its liquidity position.


Peer comparison

Sep 30, 2024